Standardization of allergen extracts for immunotherapy: where do we stand?
Authors:
- Lothar VogelLVLothar Vogel
- Stefan ViethsSVStefan Vieths
- 1 December 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 6 (6) , 470-475
Abstract
The current state of the art in allergen standardization and recent progress in the field is summarized, and future developments are discussed. The main focus of recent research in allergen standardization was on sandwich enzyme-linked immunosorbent assays or competitive tests for the quantification of individual allergens in extracts. New assays for quantifying major or minor allergens have been developed for tree and weed pollens from the Mediterranean area, grass pollens, and foods such as peanut and apple. In several cases, a good correlation with allergenic activity, measured by inhibition tests, was obtained. In addition, the potential of cellular mediator release assays in allergen standardization was evaluated in one study. Several new tests have been developed to make more major and minor allergens from various allergen sources accessible to allergen standardization programmes such as the CREATE project. It is expected that assays to determine the majority of all clinically relevant major allergens from aeroallergen sources will be available in the near future. Standardized and validated mediator release assays may be a complementary tool for evaluating the biological potency of reference allergens and for correlating allergen concentrations to biological potency.Keywords
This publication has 24 references indexed in Scilit:
- Allergen-specific immunotherapy with recombinant grass pollen allergensJournal of Allergy and Clinical Immunology, 2005
- Recombinant allergens for immunotherapy. Where do we stand?Current Opinion in Allergy and Clinical Immunology, 2004
- Vaccination with genetically engineered allergens prevents progression of allergic diseaseProceedings of the National Academy of Sciences, 2004
- Transition of recombinant allergens from bench to clinical applicationMethods, 2004
- Recombinant lipid transfer protein Cor a 8 from hazelnutJournal of Allergy and Clinical Immunology, 2004
- Genetic Engineering of Allergens: Future Therapeutic ProductsInternational Archives of Allergy and Immunology, 2002
- Identification of hazelnut major allergens in sensitive patients with positive double-blind, placebo-controlled food challenge resultsJournal of Allergy and Clinical Immunology, 2002
- Comparison of four variants of a major allergen in hazelnut (Corylus avellana) Cor a 1.04 with the major hazel pollen allergen Cor a 1.01Molecular Immunology, 2002
- FURTHER OBSERVATIONS ON THE TREATMENT OF HAY FEVER BY HYPODERMIC INOCULATIONS OF POLLEN VACCINE.The Lancet, 1911
- PROPHYLACTIC INOCULATION AGAINST HAY FEVERThe Lancet, 1911